Kirk started Iconic Therapeutics after licensing a novel treatment for wet age-related macular degeneration and cancer from Yale University.  After raising $15M in Series A funding, they had completed the pre-clinical phase of the drug’s development and were ready for the all-important Phase 1 human safety studies.  All that remained was to complete the final